{"disease":{"id":"pruritus-associated-with-atopic-dermatitis","name":"Pruritus associated with atopic dermatitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"nemolizumab","indication_name":"Pruritus associated with atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitchga","generic_name":"NEMOLIZUMAB","company_name":"Maruho Co., Ltd.","drug_phase":"marketed","molecular_target":"Interleukin-31 receptor subunit alpha","drug_class":"Interleukin-31 Receptor alpha Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Nemolizumab works by binding to the interleukin-31 receptor subunit alpha, blocking the action of interleukin-31 and reducing inflammation and itching."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02004041","title":"Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Vanda Pharmaceuticals","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}